SIGA Share Price

Open 3.05 Change Price %
High 3.10 1 Day 0.05 1.64
Low 3.01 1 Week -0.02 -0.64
Close 3.10 1 Month -0.12 -3.73
Volume 281245 1 Year 0.75 31.91
52 Week High 3.88
52 Week Low 0.00
SIGA Important Levels
Resistance 2 3.18
Resistance 1 3.15
Pivot 3.07
Support 1 3.05
Support 2 3.02
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
VRTA 4.50 38.46%
ATEA 2.50 32.98%
ATEA 2.50 32.98%
KIRK 10.98 31.03%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TWER 0.10 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

SIGA Technologies Inc. (NASDAQ: SIGA)

SIGA Technical Analysis 2
As on 22nd Aug 2017 SIGA Share Price closed @ 3.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.04 & Strong Sell for SHORT-TERM with Stoploss of 3.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
SIGA Target for August
1st Target up-side 5.02
2nd Target up-side 6.31
3rd Target up-side 7.61
1st Target down-side 1.32
2nd Target down-side 0.03
3rd Target down-side -1.27
SIGA Other Details
Segment EQ
Market Capital 152333136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.siga.com
SIGA Address
SIGA
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
Phone: 212-672-9100
Fax: 212-697-3130
SIGA Latest News
Interactive Technical Analysis Chart SIGA Technologies Inc. ( SIGA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SIGA Technologies Inc.
SIGA Business Profile
SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.